Oculis Holding Stock Price, News & Analysis

Oculis (NASDAQ:OCS) announced the vesting and settlement of Restricted Stock Units (RSUs) for its directors, specifically for CEO Riad Sherif. The company has published the required notifications of transactions by persons discharging managerial responsibilities, in compliance with regulatory requirements.

Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic diseases, has announced its participation in several upcoming investor conferences in May 2025.

The company's leadership team, including CEO Riad Sherif, MD and CFO Sylvia Cheung, will present at four major conferences: Bio€quity Europe in Bruges, Bank of America Healthcare Conference in Las Vegas, H.C. Wainwright Annual BioConnect at Nasdaq in New York, and Stifel Virtual Ophthalmology Forum. One-on-one meetings with investors will be available during these events.

Webcast links for the presentations will be accessible on the Events & Presentation page of the Oculis website under the Investors & Media section.

Oculis (OCS) has announced the filing of notifications regarding annual equity incentive awards granted to its board directors. The notifications specifically pertain to transactions by T Rosenberg, C Ackermann, A Khanani, and R Warner as part of the June 2025 Board of Directors grant program. These disclosures are standard regulatory filings required for transactions by persons discharging managerial responsibilities within the company.

Oculis Holding AG (Nasdaq: OCS) held its 2025 Annual General Meeting on June 4, where shareholders approved all agenda items. The company reported a loss of CHF 5.18 million for 2024, with an accumulated balance sheet loss of CHF 46.58 million. Anthony Rosenberg was re-elected as Board chairperson, along with seven other board members. Shareholders approved compensation packages including USD 572,000 for non-executive board members' fixed compensation, USD 2.15 million for equity-based compensation, and executive committee compensation including USD 2.48 million fixed compensation and USD 1.75 million variable compensation for 2026. Additionally, a maximum of USD 15.5 million was approved for executive equity-based compensation. The meeting also approved a capital band of 27.27 million registered shares and a conditional share capital for employees of CHF 124,800.

Oculis (OCS) announced the vesting and settlement of Restricted Stock Units (RSUs) for two company directors - Anthony Rosenberg and Arshad Khanani. The transactions occurred in May 2025 as part of previously granted RSU compensation packages. This type of transaction is a routine part of executive compensation where RSUs convert to actual shares based on a predetermined vesting schedule.

Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic diseases, has announced its participation in two major investor conferences in June 2025. CEO Riad Sherif will present a fireside chat at the Goldman Sachs Annual Healthcare Conference in Miami on June 10th from 9:20 to 9:55am ET. Additionally, Dr. Sherif will attend the J.P. Morgan European Healthcare Conference in London on June 12th. The company will be available for one-on-one meetings during both conferences, with interested investors advised to contact conference representatives for meeting arrangements. Webcast links will be made available on Oculis's website under the Investors & Media section.

Oculis Holding AG (Nasdaq: OCS) has announced its 2025 Annual General Meeting, scheduled for June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland. The meeting will take place at 3:00 p.m. CEST / 9:00 a.m. EDT and will be held both in-person and via broadcast.

Prior to the AGM, the company will host a virtual information session on May 19, 2025 from 4:00 to 5:00 p.m. CEST, where management will present the meeting proposals and address shareholder questions. Meeting materials and webcast replay will be available on the Oculis website.

Oculis (OCS) reported Q1 2025 financial results and significant progress across its ophthalmology pipeline. The company ended Q1 with $206.3 million in cash, providing runway into early 2028, bolstered by a $100 million financing in February 2025. Key developments include: completion of Phase 3 DIAMOND trials enrollment with over 800 patients for OCS-01 in diabetic macular edema (DME), with topline results expected Q2 2026; positive Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis; and advancement of Licaminlimab (OCS-02) with a genotype-based development plan for dry eye disease. The company reported a Q1 net loss of $36.9 million ($0.77 per share), compared to $18.4 million ($0.50 per share) in Q1 2024.

Oculis Holding AG (Nasdaq: OCS) reported Q1 2025 financial results and significant progress across its pipeline. The company ended Q1 with $206.3 million in cash, providing runway into early 2028, bolstered by a $100 million financing in February 2025. Key developments include:

- OCS-01: Completed enrollment of over 800 patients in Phase 3 DIAMOND trials for diabetic macular edema (DME), with topline results expected Q2 2026

- Licaminlimab (OCS-02): Aligned with FDA on genotype-based development plan for dry eye disease, with first registrational trial planned for 2H 2025

- Privosegtor (OCS-05): Reported positive Phase 2 ACUITY trial results in acute optic neuritis, showing neuroprotective benefits

Q1 2025 net loss was CHF 33.2 million ($36.9 million), or CHF 0.69 per share, compared to CHF 16.1 million in Q1 2024. R&D expenses increased to CHF 14.8 million, primarily due to clinical trial costs.